Cornell PhD · MIT Postdoc · Georgetown Emeritus

Five decades at the frontier of biosensors, semiconductors & medical devices.

Senior science and engineering consulting for companies translating physical-electronic and electrochemical innovation into clinical, regulatory, and commercial impact.

Engage for Consulting View Research
200+
Peer-reviewed Publications
19+
Issued & Pending Patents
$1.7M+
NIH SBIR Awards (PI)
30+
PhD & MSc Students Supervised
50 yrs
Research & Industry Practice
5K+
Students Taught
About the practice

An uncommon combination of theoretical depth and shop-floor practice.

Trained as a theoretical physicist at Cornell and a materials chemist at MIT, Dr. Currie has spent fifty years working at the interface where fundamental science becomes commercial technology — designing and manufacturing semiconductor heterostructures, thin-film coatings, microfluidic devices, electrochemical biosensors, and full FDA-pathway medical instruments. He has been a tenured Full Professor at three universities, the founding director of four research laboratories, the inventor or co-inventor of more than 19 patents, and a continuously practicing Professional Engineer in electrical engineering and engineering physics.

Today, as Chief Science Officer of Cambridge Medical Technologies, LLC and Professor Emeritus at Georgetown University, he advises medical-device companies, semiconductor groups, federal funders, and law firms on the topics where he has personally built, tested, published, and patented the underlying science.

Areas of expertise

Six domains, deeply earned.

01 / DOMAIN

Transdermal Biosensors & Interstitial-Fluid Analysis

Invention, design, fabrication, and clinical validation of non-invasive painless transdermal sampling and analysis devices for glucose, lactate, ethyl alcohol, bilirubin, cholesterol, melatonin, and troponin in interstitial fluid. Includes hydrogel electrochemistry, redox cofactor incorporation, ELISA-style on-electrode bioassays, and multi-analyte panels.

02 / DOMAIN

Thin-Film Semiconductor Devices & Photonics

Si MOS, polycrystalline and amorphous silicon, InP/InGaAs heterostructure insulated-gate FETs operating to 6 GHz, GaAs waveguide modulators, quantum-confined Stark-effect devices, and III-V scintillating radiation detectors. From band-alignment engineering to wafer-scale fabrication.

03 / DOMAIN

MEMS, Microfluidics & Electrochemical Microsensors

SU-8 multi-layer dermal patches, PDMS microfluidics, sputtered NASICON solid-electrolyte CO₂/NO₂/SO₂ sensors, screen-printed and evaporated-gold electrode arrays, bistable electrothermal CMOS actuators, and dry-release polymer structures for fluidic encapsulation.

04 / DOMAIN

FDA, ISO 13485 & Regulatory Strategy

Pathway selection between 510(k), De Novo, and PMA for novel non-invasive monitoring devices; QMS implementation; SOP authoring; design controls; risk management to ISO 14971; clinical-evaluation reports; and audit preparation, coordinated with regulatory consulting and contract manufacturing partners.

05 / DOMAIN

Federal Grant Strategy & Scientific Writing

NIH SBIR/STTR (PI on Phase I and Phase II awards totaling more than $1.7M), NIAAA Clinical Research Program, ARPA-H, BARDA, DARPA, Army Research Office. Specific aims, innovation, approach, milestones, commercialization plans, and biosketch preparation in NIH SF424 format.

06 / DOMAIN

IP Portfolio & Freedom-to-Operate

Patent prosecution from invention disclosure through claim charts, PCT national-phase entries (US, EP, China, India), continuation and CIP strategy, FTO analysis against Abbott FreeStyle Libre, Dexcom, Biolinq, SCRAM Systems, Trividia, and other competitors. Coordination with patent counsel.

"The quantitative measurement paradigm requires the invention of new devices, made of novel materials, fabricated using atomic and molecular deposition and patterning instruments, and analyzed using adapted methods."
Selected current activities

What I am working on right now.

Continuing development of CMT's noninvasive transdermal biosensor platform for blood analyte monitoring, including the wearable alcohol-detection program with McLean Hospital and Harvard Medical School; the broader multi-analyte clasp product targeting glucose, lactate, and additional biomarkers; ISO 13485 certification and QMS implementation; and federal grant pipelines spanning NIH, NIAAA, ARPA-H, and BARDA. Active research collaborations include Dr. Nathan Shapiro at Beth Israel Deaconess Medical Center / Harvard, Dr. Sergey Piletsky at the University of Leicester, and Dr. Bill Jackson at Base Pair Biotechnologies. Manufacturing and engineering partners include Phillips-Medisize, Voler Systems, Anritsu, and Tozaro. IP portfolio management is coordinated with Marbury Law Group.

Engagement

Available for retained and project-based consulting.

Typical engagements include due-diligence reviews for investors and acquirers; expert review of grant proposals or peer-reviewed manuscripts; design-of-experiment guidance for biosensor calibration and validation studies; semiconductor process or thin-film failure analysis; patent claim construction and validity opinions; and serving on technical advisory boards for early-stage medical-device and semiconductor companies.

Engagement Models & Rates Send an Inquiry